The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Caris Life Sciences Inc shares valued at $157,500 were purchased by Denton John Russel on Jun 20 ’25. At $21.00 per share, Denton John Russel acquired 7,500 shares. The insider’s holdings grew to 123,591 shares worth approximately $4.57 million following the completion of this transaction.
Also, Brille Brian J purchased 30,000 shares, netting a total of over 630,000 in proceeds. Following the buying of shares at $21.00 each, the insider now holds 162,428 shares.
As published in their initiating research note from Wolfe Research on July 14, 2025, Caris Life Sciences Inc [CAI] has been an Outperform and the price target has been revised to $32. Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in mid July. As of July 14, 2025, JP Morgan has initiated its “an Overweight” rating for CAI. Earlier on July 14, 2025, Guggenheim initiated its rating. Their recommendation was “a Buy” for CAI stock.
Analyzing CAI Stock Performance
On last trading session, Caris Life Sciences Inc [NASDAQ: CAI] rose 7.91% to $36.99. The stock’s lowest price that day was $33.34, but it reached a high of $37.62 in the same session. During the last five days, there has been a surge of approximately 29.38%.
Support And Resistance Levels for Caris Life Sciences Inc (CAI)
According to the 24-hour chart, there is a support level at 34.35, which, if violated, would cause prices to drop to 31.70. In the upper region, resistance lies at 38.63. The next price resistance is at 40.26. RSI (Relative Strength Index) is 72.46 on the 14-day chart, showing overbought technical sentiment.
Is Caris Life Sciences Inc subject to short interest?
Stocks of Caris Life Sciences Inc saw a sharp steep in short interest on 2025-07-31 dropping by 66308.0 shares to 1.29 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 1.36 million shares. A decline of -5.12% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.24 of the overall float, the days-to-cover ratio (short ratio) decline to 2.24.
Which companies own the most shares of Caris Life Sciences Inc (CAI)?
In terms of Caris Life Sciences Inc share price expectations, FactSet research, analysts set an average price target of 38.5 in the next 12 months, up nearly 12.31% from the previous closing price of $34.28. Analysts anticipate Caris Life Sciences Inc stock to reach 45 by 2025, with the lowest price target being 32. On July 14, 2025, Evercore ISI assigned a price target of “an Outperform” to the stock and initiated coverage with a $33.
